More on SMMT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.37 |
|
|||
| Open | $15.39 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $4.26 | ||||
| Day High | $15.41 | ||||
| Day Low | $14.56 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,328,508 | ||||
- H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
- Form 4 Summit Therapeutics Inc. For: Oct 08 Filed by: Anand Bhaskar
- Form PRE 14A Summit Therapeutics Inc. For: Oct 06
- Bernstein SocGen: 'We still think investors should not be long Summit Therapeutics plc (SMMT)'
- AstraZeneca closes $2 billion equity stake in Summit Therapeutics
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC
- AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Entities mentioned with SMMT
- Twitter | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Equity Offerings | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
